Survival in beta-thalassaemia major in the UK: data from the UK Thalassaemia Register

Lancet. 2000 Jun 10;355(9220):2051-2. doi: 10.1016/S0140-6736(00)02357-6.

Abstract

About 50% of UK patients with beta-thalassaemia major die before the age of 35 years, mainly because conventional iron-chelation therapy is too burdensome for full adherence. Patients require an individually-tailored treatment plan incorporating new, more tolerable approaches.

Publication types

  • Letter
  • Research Support, Non-U.S. Gov't

MeSH terms

  • Adolescent
  • Adult
  • Chelating Agents / therapeutic use*
  • Chelation Therapy*
  • Child
  • Cohort Studies
  • Deferoxamine / therapeutic use*
  • Humans
  • Iron
  • Patient Compliance
  • Registries
  • Survival Analysis
  • United Kingdom / epidemiology
  • beta-Thalassemia / drug therapy*
  • beta-Thalassemia / mortality*

Substances

  • Chelating Agents
  • Iron
  • Deferoxamine